0001004878-18-000012.txt : 20180119
0001004878-18-000012.hdr.sgml : 20180119
20180118193657
ACCESSION NUMBER: 0001004878-18-000012
CONFORMED SUBMISSION TYPE: 424B3
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20180119
DATE AS OF CHANGE: 20180118
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 424B3
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-186103
FILM NUMBER: 18535165
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
424B3
1
prosupp186103jan-18.txt
PROSUPP S WARRANTS 186103
PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplements dated December 19 Registration No. 333-186103
and December 26, 2013)
CEL-SCI CORPORATION
Series S Warrants
On January 12, 2018 the exercise price of the Company's outstanding Series
S warrants (CUSIP number 150837177), that are publicly traded under the symbol
"CVM WS" on the NYSE American, was changed to $3.00 per share for a three month
period which will end on April 12, 2018. After this date, the exercise price
will revert back to $31.25 per share of common stock. As a result of the reverse
stock split which became effective on the NYSE American on June 15, 2017, 25
Series S warrants are required to purchase one share of common stock. The Series
S warrants expire on October 11, 2018.
..
Prospectus Supplement dated January 16, 2018